NeoGenomics (NEO) Reports In-Line Q2 EPS

NeoGenomics (NASDAQ: NEO) reported Q2 EPS of $0.01, in-line with the analyst estimate of $0.01. Revenue for the quarter came in at $20.7 million versus the consensus estimate of $19.84 million.

For earnings history and earnings-related data on NeoGenomics (NEO) click here.

You May Also Be Interested In

• BMO Capital Upgrades Casey's General Stores (CASY) to Outperform, 'Opportunity Knocks'
• TD Cowen Upgrades PBF Energy (PBF) to Hold
• Zymeworks to buy Theravance Biopharma for $17 per share